These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 4537633)

  • 1. Hemolysis due to anti-A and anti-B in factor VIII preparations.
    Seeler RA
    Arch Intern Med; 1972 Jul; 130(1):101-3. PubMed ID: 4537633
    [No Abstract]   [Full Text] [Related]  

  • 2. [5 cases of hemolytic transfusion reactions induced by anti-E].
    Tong H; Yu R
    Hunan Yi Ke Da Xue Xue Bao; 2000 Oct; 25(5):476, 486. PubMed ID: 12212124
    [No Abstract]   [Full Text] [Related]  

  • 3. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of various physicochemical factors for hemagglutination and dissociation of hemagglutinins. II. Studies on ABO and Rh antibody dissociation].
    Hubrich W; Schneeweiss B; Tacke A; Kleinau H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1973; 99(2):249-58. PubMed ID: 4122969
    [No Abstract]   [Full Text] [Related]  

  • 5. No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's disease.
    Castaman G; Rodeghiero F
    Thromb Haemost; 1995 Mar; 73(3):551-2. PubMed ID: 7667843
    [No Abstract]   [Full Text] [Related]  

  • 6. Compatible transfusion therapy for paroxysmal cold hemoglobinuria.
    Rausen AR; LeVine R; Hsu TC; Rosenfield RE
    Pediatrics; 1975 Feb; 55(2):275-8. PubMed ID: 1118213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hemolytic reactions following transfusion of "compatible" blood].
    Magni E; Rossetti V
    Minerva Med; 1972 Jun; 63(45):2525-35. PubMed ID: 5035400
    [No Abstract]   [Full Text] [Related]  

  • 8. [Blood group determination and compatability testing].
    Metaxas M
    Schweiz Med Wochenschr; 1971 Oct; 101(42):1493-5. PubMed ID: 5004033
    [No Abstract]   [Full Text] [Related]  

  • 9. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components.
    Rowley SD; Liang PS; Ulz L
    Bone Marrow Transplant; 2000 Oct; 26(7):749-57. PubMed ID: 11042656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.
    Bergamaschini L; Mannucci PM; Federici AB; Coppola R; Guzzoni S; Agostoni A
    J Lab Clin Med; 1995 Mar; 125(3):348-55. PubMed ID: 7897302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of anti-Vel-antibodies].
    Bergmann H; Drescher KH
    Bibl Haematol; 1971; 37():434-42. PubMed ID: 5003068
    [No Abstract]   [Full Text] [Related]  

  • 12. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
    Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
    Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.
    Schleef M; Strobel E; Dick A; Frank J; Schramm W; Spannagl M
    Br J Haematol; 2005 Jan; 128(1):100-7. PubMed ID: 15606555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
    Rivard GE; Aledort L;
    Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [On the problem of ABO-incompatibility].
    Rudelić I
    Med Klin; 1967 Nov; 62(47):1825-7. PubMed ID: 5588927
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemolysins and isoagglutinins in substitute preparations containing factor VIII].
    Göbel U; Ranke M
    Blut; 1972 Jun; 24(6):365-71. PubMed ID: 5057724
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
    Berntorp E
    Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.